What is the ticker symbol for Connect Biopharma?

Connect Biopharma trades under the ticker CNTB on NASDAQ.

What sector does Connect Biopharma operate in?

Connect Biopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CNTB in a portfolio?

PortView shows CNTB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Connect Biopharma (CNTB) Stock Analysis

NASDAQHealthcareBiotechnology

$2.57+8.69%

1-year price historyRange $1.32 – $3.69

52-week range$2.57

$1.23$3.82

What Connect Biopharma does

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company dedicated to discovering and advancing immune modulators. Its primary objective is to develop treatments for serious autoimmune diseases and various inflammatory conditions. The company's lead investigational therapy is CBP-201, an anti-interleukin-4 receptor alpha antibody. This candidate is currently in Phase IIb clinical trials, targeting inflammatory allergic diseases such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Additionally, Connect Biopharma's pipeline includes CBP-307, a small molecule designed to modulate sphingosine 1-phosphate receptor 1. This receptor plays a crucial role in regulating T cell movement from lymph nodes into the bloodstream. CBP-307 is in Phase II development for treating autoimmune-related inflammatory disorders. Another preclinical-stage asset, CBP-174, is an orally administered small molecule histamine receptor 3 antagonist, being investigated for chronic pruritus (itch) associated with skin inflammation. The portfolio also features CBP-233, a humanized antibody in preclinical development that targets interleukin-33, a cytokine recognized for its involvement in T helper 2 inflammation. Established in 2012, the company maintains its headquarters in Taicang, China.

Key metrics

Market cap

$161.50M

P/E (TTM)

-4.20

EPS (TTM)

$-0.61

Beta

-0.22

Dividend yield

0.00%

Revenue / share

$0.05

50-day avg

$2.27

200-day avg

$2.47

52-week high

$3.82

52-week low

$1.23

CEO

Barry D. Quart

ETFs linked to CNTB

Broad-market and Healthcare sector ETFs an investor holding Connect Biopharma is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how CNTB fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CNTB in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Connect Biopharma?: Connect Biopharma trades under the ticker CNTB on NASDAQ.
Which exchange is CNTB listed on?: CNTB is listed on NASDAQ.
What sector does Connect Biopharma operate in?: Connect Biopharma is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze CNTB in a portfolio?: PortView shows CNTB's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.